TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound With Fine Needle Aspiration (EUS/FNA), Direct Visualization, and Confocal Laser-induced Endomicroscopy-A Pilot Study
Brief Summary: The purpose of this study is to assess the yield of combination modalities in the diagnosis of pancreatic cysts using EUS/FNA, Fiber optics (direct visualization probe), and prototype needle based confocal laser-induced endomicroscopy miniprobe (nCLE).


Options:
A: Intervention Type: DEVICE; Name: Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe; Assigned to Arm(s): N/A
B: Arm Label: 1.EUS-FNA with or without suction; Type: EXPERIMENTAL; Interventions: Procedure: 1.EUS-FNA with or without suction | Arm Label: 2.Pushing the stylet or injecting air; Type: EXPERIMENTAL; Interventions: Procedure: 2.Pushing the stylet or injecting air | Intervention Type: PROCEDURE; Name: 1.EUS-FNA with or without suction; Assigned to Arm(s): 1.EUS-FNA with or without suction | Intervention Type: PROCEDURE; Name: 2.Pushing the stylet or injecting air; Assigned to Arm(s): 2.Pushing the stylet or injecting air
C: Arm Label: Pancreatic adenocarcinoma; Type: N/A; Interventions: N/A | Arm Label: Chronic pancreatitis; Type: N/A; Interventions: N/A
D: Arm Label: Lymph nodes, pancreatic masses & cysts; Type: OTHER; Interventions: Procedure: EUS-FNA, Device: nCLE | Intervention Type: PROCEDURE; Name: EUS-FNA; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts | Intervention Type: DEVICE; Name: nCLE; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators conducted a pilot study including 17 patients with liver cirrhosis showing that a moderate exercise programme during three months increased thigh circumference,exercise tolerance and quality of life without adverse effects. The present study aim to more accurately evaluate the effect of exercise on muscle mass, effort tolerance and inflammatory response in patients with cirrhosis. This study will include 30 patients with compensated liver cirrhosis that will be randomized into two groups: exercise group and control group. Evaluation of muscle mass, effort tolerance, inflammatory response and quality of life will be made at the beginning and at the end of the study.


Options:
A: Arm Label: Physical training - No encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - No encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Arm Label: Physical training - Early encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - Early encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training - Early encephalopathy, Physical training - No encephalopathy | Intervention Type: OTHER; Name: Diet intervention; Assigned to Arm(s): Control - Early encephalopathy, Control - No encephalopathy, Physical training - Early encephalopathy, Physical training - No encephalopathy
B: Arm Label: Diet+Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Diet + exercise | Intervention Type: BEHAVIORAL; Name: Diet + exercise; Assigned to Arm(s): Diet+Exercise
C: Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: Usual care group; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care group
D: Arm Label: Exercise, relaxation; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise + relaxation | Arm Label: Relaxation; Type: OTHER; Interventions: Other: Relaxation | Intervention Type: OTHER; Name: Exercise + relaxation; Assigned to Arm(s): Exercise, relaxation | Intervention Type: OTHER; Name: Relaxation; Assigned to Arm(s): Relaxation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Brief Summary: To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone


Options:
A: Arm Label: Lapatinib Oral Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Intervention Type: DRUG; Name: Oral lapatinib tablets or placebo tablets; Assigned to Arm(s): Lapatinib Oral Tablets, Placebo Control
B: Arm Label: open label; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): open label | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): open label
C: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: MM-121 (SAR256212) + Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: MM-121, Drug: Paclitaxel | Intervention Type: DRUG; Name: MM-121; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel, Paclitaxel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
B: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
C: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
B: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
C: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, 10 mg, Drug: Rivaroxaban, 7.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban, 10 mg; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Rivaroxaban, 7.5 mg; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1; Type: OTHER; Interventions: Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed | Arm Label: Group 2; Type: OTHER; Interventions: Drug: Group 2: control group with enoxaparin 40mg/d | Intervention Type: DRUG; Name: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Group 2: control group with enoxaparin 40mg/d; Assigned to Arm(s): Group 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: Experimental group (SCD + GCS + LMWH); Type: EXPERIMENTAL; Interventions: Device: SCD, Device: GCS, Drug: LMWH | Arm Label: Control group (GCS + LMWH); Type: ACTIVE_COMPARATOR; Interventions: Device: GCS, Drug: LMWH | Intervention Type: DEVICE; Name: SCD; Assigned to Arm(s): Experimental group (SCD + GCS + LMWH) | Intervention Type: DEVICE; Name: GCS; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH) | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
D: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: Group 1; Type: OTHER; Interventions: Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed | Arm Label: Group 2; Type: OTHER; Interventions: Drug: Group 2: control group with enoxaparin 40mg/d | Intervention Type: DRUG; Name: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Group 2: control group with enoxaparin 40mg/d; Assigned to Arm(s): Group 2
B: Arm Label: Nebulized Heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Sodium-chloride | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Nebulized Heparin | Intervention Type: DRUG; Name: 0.9% Sodium-chloride; Assigned to Arm(s): Placebo
C: Arm Label: Full-dose anticoagulation (FDAC); Type: EXPERIMENTAL; Interventions: Drug: Unfractionated Heparin IV, Drug: Enoxaparin 1 mg/kg, Drug: Clopidogrel | Arm Label: Standard-dose prophylactic anticoagulation (SDPAC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Unfractionated heparin SC, Drug: Enoxaparin 40 mg SC | Intervention Type: DRUG; Name: Unfractionated Heparin IV; Assigned to Arm(s): Full-dose anticoagulation (FDAC) | Intervention Type: DRUG; Name: Enoxaparin 1 mg/kg; Assigned to Arm(s): Full-dose anticoagulation (FDAC) | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Full-dose anticoagulation (FDAC), Standard-dose prophylactic anticoagulation (SDPAC) | Intervention Type: DRUG; Name: Unfractionated heparin SC; Assigned to Arm(s): Standard-dose prophylactic anticoagulation (SDPAC) | Intervention Type: DRUG; Name: Enoxaparin 40 mg SC; Assigned to Arm(s): Standard-dose prophylactic anticoagulation (SDPAC)
D: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
B: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
D: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
C: Arm Label: Cohort 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 1: Apixaban, 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2: Apixaban, 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Cohort 1: Apixaban, 10 mg, Cohort 1: Apixaban, 20 mg, Cohort 1: Apixaban, 5 mg, Cohort 2: Apixaban, 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Placebo, Cohort 2: Placebo
D: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients
Brief Summary: This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
B: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
C: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A

Answer: B